Compare Stocks: PLSE, BAX, PEN, and SNN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAX Baxter International	$24.22 -0.6%	$25.34	$15.73 ▼ $30.00	$12.51B	0.65	7.92 million shs	1.81 million shs
PEN Penumbra	$317.31 +0.1%	$321.66	$221.26 ▼ $362.41	$12.50B	0.7	602,111 shs	142,242 shs
PLSE Pulse Biosciences	$48.42 -2.7%	$47.99	$12.56 ▼ $58.90	$3.41B	1.57	389,838 shs	99,044 shs
SNN Smith & Nephew SNATS	$27.10 +0.8%	$28.79	$26.12 ▼ $37.51	$11.38B	0.53	1.27 million shs	538,808 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAX Baxter International	+0.25%	+3.45%	-5.82%	+10.58%	+5.04%
PEN Penumbra	-0.13%	-0.55%	-1.64%	-0.13%	+24.14%
PLSE Pulse Biosciences	-1.49%	-2.24%	-6.56%	+76.98%	+155.78%
SNN Smith & Nephew SNATS	-0.26%	-0.27%	-7.11%	-10.48%	-25.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAX Baxter International	$24.22 -0.6%	$25.34	$15.73 ▼ $30.00	$12.51B	0.65	7.92 million shs	1.81 million shs
PEN Penumbra	$317.31 +0.1%	$321.66	$221.26 ▼ $362.41	$12.50B	0.7	602,111 shs	142,242 shs
PLSE Pulse Biosciences	$48.42 -2.7%	$47.99	$12.56 ▼ $58.90	$3.41B	1.57	389,838 shs	99,044 shs
SNN Smith & Nephew SNATS	$27.10 +0.8%	$28.79	$26.12 ▼ $37.51	$11.38B	0.53	1.27 million shs	538,808 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAX Baxter International	+0.25%	+3.45%	-5.82%	+10.58%	+5.04%
PEN Penumbra	-0.13%	-0.55%	-1.64%	-0.13%	+24.14%
PLSE Pulse Biosciences	-1.49%	-2.24%	-6.56%	+76.98%	+155.78%
SNN Smith & Nephew SNATS	-0.26%	-0.27%	-7.11%	-10.48%	-25.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAX Baxter International	1.85	Reduce	$21.73	-10.27% Downside
PEN Penumbra	2.18	Hold	$367.07	15.68% Upside
PLSE Pulse Biosciences	2.86	Moderate Buy	$53.20	9.87% Upside
SNN Smith & Nephew SNATS	2.00	Hold	$31.91	17.77% Upside

Current Analyst Ratings Breakdown

Latest PLSE, BAX, PEN, and SNN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	BAX Baxter International	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$20.00
10/6/2026	PLSE Pulse Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$43.00 ➝ $58.00
10/5/2026	BAX Baxter International	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $27.00
9/24/2026	SNN Smith & Nephew SNATS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/11/2026	SNN Smith & Nephew SNATS	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.88
9/9/2026	PLSE Pulse Biosciences	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/8/2026	SNN Smith & Nephew SNATS	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/8/2026	SNN Smith & Nephew SNATS	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/4/2026	SNN Smith & Nephew SNATS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAX Baxter International	$11.47B	1.09	$5.68 per share	4.26	$11.87 per share	2.04
PEN Penumbra	$1.50B	8.31	$4.30 per share	73.76	$36.45 per share	8.71
PLSE Pulse Biosciences	$350K	9,794.88	N/A	N/A	$1.19 per share	40.69
SNN Smith & Nephew SNATS	$6.16B	1.85	$3.45 per share	7.85	$12.45 per share	2.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAX Baxter International	-$957M	-$2.07	N/A	12.11	3.66	-9.27%	16.57%	5.24%	10/29/2026 (Estimated)
PEN Penumbra	$177.69M	$4.07	77.96	51.85	2.18	10.67%	10.50%	8.17%	11/4/2026 (Estimated)
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	11/4/2026 (Estimated)
SNN Smith & Nephew SNATS	$625M	N/A	N/A	11.73	1.45	N/A	N/A	N/A	N/A

Latest PLSE, BAX, PEN, and SNN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	PEN Penumbra	$1.20	N/A	N/A	N/A	$401.41 million	N/A
11/4/2026	Q3 2026	PLSE Pulse Biosciences	-$0.35	N/A	N/A	N/A	$0.60 million	N/A
10/29/2026	Q3 2026	BAX Baxter International	$0.5180	N/A	N/A	N/A	$2.91 billion	N/A
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
7/30/2026	Q2 2026	BAX Baxter International	$0.3665	$0.56	+$0.1935	$0.24	$2.80 billion	$2.96 billion
7/30/2026	Q2 2026	PEN Penumbra	$1.16	$0.88	-$0.28	$0.88	$389.64 million	$390.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAX Baxter International	$0.04	0.16%	-11.54%	N/A	N/A
PEN Penumbra	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A
SNN Smith & Nephew SNATS	$0.59	2.20%	N/A	N/A	N/A

Latest PLSE, BAX, PEN, and SNN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2026	SNN Smith & Nephew SNATS		$0.3120	2.36%	10/2/2026	10/2/2026	11/6/2026
7/29/2026	BAX Baxter International	quarterly	$0.01	0.15%	8/28/2026	8/28/2026	10/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAX Baxter International	1.39	1.95	1.32
PEN Penumbra	0.01	5.75	3.86
PLSE Pulse Biosciences	N/A	9.63	9.61
SNN Smith & Nephew SNATS	0.62	2.14	1.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAX Baxter International	90.19%
PEN Penumbra	88.88%
PLSE Pulse Biosciences	76.95%
SNN Smith & Nephew SNATS	25.64%

Insider Ownership

Company	Insider Ownership
BAX Baxter International	0.17%
PEN Penumbra	2.90%
PLSE Pulse Biosciences	74.00%
SNN Smith & Nephew SNATS	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAX Baxter International	37,500	517.00 million	516.12 million	Optionable
PEN Penumbra	4,700	39.39 million	38.25 million	Optionable
PLSE Pulse Biosciences	116	70.80 million	18.41 million	Optionable
SNN Smith & Nephew SNATS	16,988	419.93 million	415.73 million	Optionable

PLSE, BAX, PEN, and SNN Headlines

Recent News About These Companies

Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

October 6 at 4:00 AM | globenewswire.com

Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.

October 6 at 4:00 AM | globenewswire.com

Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal

October 6 at 4:00 AM | globenewswire.com

Smith & Nephew SNATS (NYSE:SNN) Sets New 52-Week Low - Should You Sell?

October 1, 2026 | marketbeat.com

Smith Nephew schedules $350 million note redemption

October 1, 2026 | americanbankingnews.com

Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

September 30, 2026 | zacks.com

Smith & Nephew SNATS, Inc. (SNN) to Distribute Dividend of $0.31 on November 6th

September 30, 2026 | americanbankingnews.com

Il titolo azionario di Smith & Nephew tocca il minimo a 52 settimane a 27,05 USD

September 23, 2026 | it.investing.com

Smith & Nephew Snats (SNN) Gets a Hold from BTIG

September 23, 2026 | theglobeandmail.com

MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

September 23, 2026 | globenewswire.com

Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

September 23, 2026 | globenewswire.com

Smith & Nephew SNATS (NYSE:SNN) Sets New 12-Month Low - Time to Sell?

September 23, 2026 | marketbeat.com

Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Recommendation of "Hold" from Analysts

September 22, 2026 | marketbeat.com

Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026

September 21, 2026 | globenewswire.com

1,550,110 Shares in Smith & Nephew SNATS, Inc. $SNN Bought by Bank of America Corp DE

September 19, 2026 | marketbeat.com

Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

September 16, 2026 | accessnewswire.comA

Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds

September 15, 2026 | accessnewswire.comA

Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued

September 14, 2026 | gurufocus.com

Smith & Nephew SNATS, Inc. $SNN Shares Acquired by Tidal Investments LLC

September 13, 2026 | marketbeat.com

Wall Street Zen Upgrades Smith & Nephew SNATS (NYSE:SNN) to "Buy"

September 13, 2026 | marketbeat.com

Smith & Nephew Raises $700 Million in 10‑Year U.S. Dollar Notes

September 12, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PLSE, BAX, PEN, and SNN Company Descriptions

Baxter International NYSE:BAX

$24.22 -0.15 (-0.60%)

As of 01:28 PM Eastern

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Penumbra NYSE:PEN

$317.31 +0.26 (+0.08%)

As of 01:27 PM Eastern

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Pulse Biosciences NASDAQ:PLSE

$48.42 -1.33 (-2.67%)

As of 01:28 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Smith & Nephew SNATS NYSE:SNN

$27.10 +0.23 (+0.84%)

As of 01:27 PM Eastern

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLSE, BAX, PEN, and SNN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLSE, BAX, PEN, and SNN Earnings

Compare Dividends

Latest PLSE, BAX, PEN, and SNN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLSE, BAX, PEN, and SNN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLSE, BAX, PEN, and SNN Company Descriptions

Baxter International NYSE:BAX

Penumbra NYSE:PEN

Pulse Biosciences NASDAQ:PLSE

Smith & Nephew SNATS NYSE:SNN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools